Skip to main content
. 2019 Jun 14;11(6):281. doi: 10.3390/pharmaceutics11060281

Table 2.

Comparison between responders and non-responders.

Items Responders Non-Responders p
Number of subjects 5 6
Pulmonary hypertension 4 5 /
Right heart failure 3 2 0.567
Pre respiratory rate 25.8 ± 9.4 25.8 ± 7.8 0.931
Pre FIO2 96 ± 8.9 78.3± 16.0 0.082
Pre flow 39 ± 13.4 35.8 ± 4.9 0.456
Pre SpO2 87.6 ± 12.7 90.7 ± 3.6 0.792
Pre SpO2/FIO2 92.5 ± 20.2 120 ± 25.3 0.082
Post respiratory rate 26.4 ± 4.9 26.3 ± 8.8 0.931
Post FIO2 76 ± 18.2 81.7 ± 18.3 0.662
Post flow 38 ± 12.6 35.8 ± 4.9 0.537
Post SpO2 96.6 ± 2.1 92.5 ± 2.3 0.03
Post SpO2/FIO2 133.7 ± 36 118.6 ± 28.9 0.429
Intubation 2 3 /
ICU stay 12 (7, 24) 14 (10, 21) 0.931
Hospital stay 12 (7, 24) 16 (11, 21) 0.792
Hospital survival 4 3 /